论文部分内容阅读
目的:探讨左炔诺孕酮宫内节育器与孕三烯酮治疗子宫腺肌病的临床疗效。方法:选取2013年1月至2015年10月佛山市南海区第七人民医院收治的100例子宫腺肌病患者,采取计算机随机分组法将患者分为对照组、观察组,每组50例。对照组采用孕三烯酮口服治疗,观察组采用左炔诺孕酮宫内节育器治疗。两组患者均接受为期6个月的治疗,比较两组患者治疗前后的痛经VAS评分、月经过多发生率、子宫内膜厚度、子宫体积,并比较两组患者的不良反应发生率。结果:与治疗前相比,治疗后两组患者的痛经VAS评分、月经过多发生率、子宫内膜厚度以及子宫体积均明显降低,差异具有统计学意义(P<0.05),但在治疗后,观察组的各项指标均明显更低(P<0.05)。两组患者的不良反应发生率分别为8%、10%,差异无统计学意义(P>0.05)。结论:在子宫腺肌病的临床治疗中,采用孕三烯酮、左炔诺孕酮宫内节育器治疗均能有效改善患者的临床症状,且安全性较高,尤其是左炔诺孕酮宫内节育器,其效果不仅显著,还可维持较长时间。
Objective: To investigate the clinical efficacy of levonorgestrel-induced intrauterine device and gestrinone in the treatment of adenomyosis. Methods: A total of 100 patients with adenomyosis admitted to the Seventh People’s Hospital of Nanhai District, Foshan City from January 2013 to October 2015 were selected and randomly divided into control group and observation group with 50 cases in each group. The control group was treated with gestrinone orally, and the observation group was treated with levonorgestrel IUD. The two groups of patients were treated for a period of 6 months. The VAS scores of dysmenorrhea, the incidence of menorrhagia, endometrial thickness and uterine volume were compared between the two groups before and after treatment. The incidence of adverse reactions was compared between the two groups. Results: Compared with those before treatment, the VAS score, the incidence of menorrhagia, endometrial thickness and uterine volume were significantly decreased in both groups after treatment, the difference was statistically significant (P <0.05), but after treatment , The indicators of the observation group were significantly lower (P <0.05). Adverse reactions in both groups were 8% and 10%, respectively, with no significant difference (P> 0.05). Conclusion: In the clinical treatment of adenomyosis, the treatment with gestrinone and levonorgestrel can effectively improve the clinical symptoms of patients and is safe, especially levonorgestrel IUD, the effect is not only significant, but also to maintain a longer period of time.